f FDA Approves Inavolisib Combo for PIK3CA-Mutated, HR+ Breast Cancer

References

1. FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer.2024Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive
2. JuricD. KalinskyK. TurnerN.C. JhaveriK.L. SchmidP. LoiS. SauraC. ImS-A. SunpaweravongP. LiH. MusolinoA. ZhangQ. NoweckiZ. LeungR.C-Y. ThanopoulouE. ShankarN. LeiG. DevineJ. StoutT.J. LoiblS. First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA -mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses.J. Clin. Oncol.20244216_suppl1003100310.1200/JCO.2024.42.16_suppl.1003
   [Google Scholar]
3. A study evaluating the efficacy and safety of Inavolisib + Palbociclib + Fulvestrant vs. Placebo + Palbociclib + Fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive, her2-negative, locally advanced or metastatic breast cancer. 2024, NC Patent T04191499.
   [Google Scholar]
4. HananE.J. BraunM.G. HealdR.A. MacLeodC. ChanC. ClausenS. EdgarK.A. EigenbrotC. ElliottR. EndresN. FriedmanL.S. GogolE. GuX.H. ThibodeauR.H. JacksonP.S. KieferJ.R. KnightJ.D. NanniniM. NarukullaR. PaceA. PangJ. PurkeyH.E. SalphatiL. SampathD. SchmidtS. SiderisS. SongK. Sujatha-BhaskarS. UltschM. WallweberH. XinJ. YeapS. YoungA. ZhongY. StabenS.T. Discovery of GDC-0077 (Inavolisib), a highly selective inhibitor and degrader of mutant PI3Kα.J. Med. Chem.20226524165891662110.1021/acs.jmedchem.2c0142236455032
   [Google Scholar]
5. EdgarK. HongR. SongK. SchmidtS. HafnerM. ArrazateA. WilliamsE. CruzC.D.L. OehJ. SampathD. StabenS. FriedmanL. Abstract P3-11-23: GDC-0077 is a selective PI3K alpha inhibitor with robust efficacy in PIK3CA mutant hormone-positive breast cancer models.Cancer Res.2020804pp. P311
   [Google Scholar]
6. HongR. EdgarK. SongK. StevenS. YoungA. HamiltonP. ArrazateA. De La CruzC. ChanC. PangJ. SalphatiL. BelvinM. NanniniM. StabenS. FriedmanL. SampathD. Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapiesCancer Res.2018784pp. PD41410.1158/1538‑7445.SABCS17‑PD4‑14
   [Google Scholar]
7. JhaveriK.L. AccordinoM.K. BedardP.L. CervantesA. GambardellaV. HamiltonE. ItalianoA. KalinskyK. KropI.E. OliveiraM. SchmidP. SauraC. TurnerN.C. VargaA. CheetiS. HilzS. HutchinsonK.E. JinY. Royer-JooS. PetersU. ShankarN. SchutzmanJ.L. JuricD. Phase I/Ib trial of inavolisib plus palbociclib and endocrine therapy for PIK3CA -mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer.J. Clin. Oncol.202442333947395610.1200/JCO.24.0011039236276
   [Google Scholar]
8. AndréF. CiruelosE. RubovszkyG. CamponeM. LoiblS. RugoH.S. IwataH. ConteP. MayerI.A. KaufmanB. YamashitaT. LuY.S. InoueK. TakahashiM. PápaiZ. LonginA.S. MillsD. WilkeC. HirawatS. JuricD. SOLAR-1 Study Group Alpelisib for PIK3CA -mutated, hormone receptor–positive advanced breast cancer.N. Engl. J. Med.2019380201929194010.1056/NEJMoa181390431091374
   [Google Scholar]
9. HotakiL.T. ShresthaA. BennettM.P. ValdesI.L. LeeS.H. WangY. SpillmanD. MacAulayT. HuntM. GervaisJ. MafiM. PanettaV. LooiY.H. ShumM. AtiekE. MeinckeR. RohrU.P. AinbinderD. Boehm-CaganA. LuxenburgO. CerqueiraM.R. MouawadL.S. TheesM.F.R.S. PrasadK. de ClaroR.A. Comparative expedited regulatory programs of U.S Food & Drug administration and project orbis partners.Ther. Innov. Regul. Sci.202357487588510.1007/s43441‑023‑00522‑437072651
   [Google Scholar]